This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator.
he specific aims of the original proposal were unmodified and remain as follows:
Specific Aim 2 : To promote physician awareness and patient lifestyle interventions to enhance treatment and outcomes of CV risk factors associated with Metabolic Syndrome in hypertensive African Americans.
Specific Aim 2 a: To determine the baseline state of awareness, treatment and control of the Metabolic Syndrome among community based practitioners, and provide a physician feedback and education intervention on provider diagnosis and treatment of CV risk factors associated with the Metabolic Syndrome in hypertensive African Americans. We will describe practice patterns in primary care settings, and compare the percentages of hypertensive patients who are treated with JCN7 and ATPIII guidelines and assessed for the Metabolic Syndrome before and after structured performance feedback and education(audit feedback).
Specific Aim 2 b: To develop and evaluate the effects of a culturally sensitive self management lifestyle intervention (LSI) on health behaviors, clinical outcomes and psychosocial factors in hypertensive AA with CV risk factors associated with the Metabolic Syndrome. 2b1. Primary aim To determine if participants who receive the LSI intervention demonstrate improved health behaviors over participants randomized to usual care (UC) as exhibited by: increased exercise tolerance test (treadmill), increased PA levels (Metabolic Syndrome-h/week from CAPS Questionnaire);improved dietary patterns (Block Questionnaire;3 day food records), and improved medication compliance (Hill-Bone Questionnaire). 2b2. Secondary aim: To determine if participants who receive the LSI demonstrate improved clinical outcomes over those randomized to UC as exhibited by: lower systolic and diastolic BP, lower weight, improved serum total cholesterol, high density lipoproteins, and triglyceride levels, and improved metabolic and inflammatory profile (fasting glucose, 2 hour glucose, fasting insulin, HOMA, CRP). 2b3. Tertiary aim: To determine if participants who receive the LSI experience improved health related quality of life (HRQOL) and psychosocial factors over those receiving UC as exhibited by improved overall physical and mental functioning (SF-36), lower perceived stress, lower depressive symptoms, increased social support, increased diet and PA self efficacy, and increased stage of change for PA. We proposed to carry out the study in three phases. Phase I involves a detailed assessment of hypertensive care among the Community Physician Network (CPN) practices with efforts made to standardize care.
Specific aim 2 a is addressed in phase I. In phase II, which addresses aim 2b ( """"""""develop and evaluate a culturally sensitive self-management lifestyle intervention on health behaviors"""""""") focus groups to assess concordance of planned intervention to expectations and acceptance, and a pilot study were conducted, Phase III is the clinical study involving recruitment and randomization of patients to usual care or the lifestyle intervention with baseline and follow-up data collection and analysis.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54RR026137-02
Application #
8173618
Study Section
Special Emphasis Panel (ZRR1-RI-8 (01))
Project Start
2010-07-01
Project End
2011-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
2
Fiscal Year
2010
Total Cost
$129,009
Indirect Cost
Name
Morehouse School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
102005451
City
Atlanta
State
GA
Country
United States
Zip Code
30310
Owino, Sharon; Sánchez-Bretaño, Aida; Tchio, Cynthia et al. (2018) Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI3K activity. J Pineal Res 64:
Augello, Catherine J; Noll, Jessica M; Distel, Timothy J et al. (2018) Identification of novel blood biomarker panels to detect ischemic stroke in patients and their responsiveness to therapeutic intervention. Brain Res 1698:161-169
Ofili, Elizabeth O; Pemu, Priscilla E; Quarshie, Alexander et al. (2018) DEMOCRATIZING DISCOVERY HEALTH WITH N=Me. Trans Am Clin Climatol Assoc 129:215-234
Piano, Ilaria; Baba, Kenkichi; Claudia Gargini et al. (2018) Heteromeric MT1/MT2 melatonin receptors modulate the scotopic electroretinogram via PKC? in mice. Exp Eye Res 177:50-54
Sánchez-Bretaño, Aída; Baba, Kenkichi; Janjua, Uzair et al. (2017) Melatonin partially protects 661W cells from H2O2-induced death by inhibiting Fas/FasL-caspase-3. Mol Vis 23:844-852
Laurent, Virgine; Sengupta, Anamika; Sánchez-Bretaño, Aída et al. (2017) Melatonin signaling affects the timing in the daily rhythm of phagocytic activity by the retinal pigment epithelium. Exp Eye Res 165:90-95
Chen, Xiaoming; Cobbs, Alyssa; George, Jasmine et al. (2017) Endocytosis of Albumin Induces Matrix Metalloproteinase-9 by Activating the ERK Signaling Pathway in Renal Tubule Epithelial Cells. Int J Mol Sci 18:
Simmons, Lauren J; Surles-Zeigler, Monique C; Li, Yonggang et al. (2016) Regulation of inflammatory responses by neuregulin-1 in brain ischemia and microglial cells in vitro involves the NF-kappa B pathway. J Neuroinflammation 13:237
Zhao, Xueying; Jiang, Chen; Olufade, Rebecca et al. (2016) Kidney Injury Molecule-1 Enhances Endocytosis of Albumin in Renal Proximal Tubular Cells. J Cell Physiol 231:896-907
Jockers, Ralf; Delagrange, Philippe; Dubocovich, Margarita L et al. (2016) Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol 173:2702-25

Showing the most recent 10 out of 71 publications